GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Study Details
Study Description
Brief Summary
The goal of this clinical study is to learn about the bispecific antibody GEN1046 in combination with the cancer drug pembrolizumab for treatment of participants with incurable endometrial cancer (cancer of the womb). The main questions the study aims to answer are:
-
How well GEN1046 in combination with pembrolizumab works against endometrial cancer
-
What are the potential side effects participants may experience when they are treated with GEN1046 in combination with pembrolizumab
Participants will receive both GEN1046 and pembrolizumab. All participants will receive active drug; no one will receive placebo. participants will participate in 1 of 2 cohorts. A participant will receive study treatment up to a maximum of 24 months. The study duration (including screening, treatment, and follow-up) for each participant will be about 39 months.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is an open-label multicenter study in participants with advanced (unresectable and/or metastatic) endometrial cancer to evaluate the safety and clinical activity of GEN1046 in combination with immunotherapy.
The trial consists of two cohorts:
-
Cohort A
-
Cohort B
The study will enroll approximately 80 participants in Cohort A and B (approximately 40 participants in each cohort).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort A: Pembrolizumab + GEN1046 Pembrolizumab will be administered in combination with GEN1046 as second-line (2L) or third-line (3L) therapy for dMMR/MSI-H in checkpoint inhibitor (CPI) naive participants. |
Drug: Pembrolizumab
Pembrolizumab intravenous (IV) infusion
Biological: GEN1046
GEN1046 IV infusion
|
| Experimental: Cohort B: Pembrolizumab + GEN1046 Pembrolizumab will be administered in combination with GEN1046 as 2L or 3L therapy for mismatch repair deficient/ microsatellite instability-high (dMMR/MSI-H) participants who had prior exposure to programmed cell death protein/ programmed death ligand 1 (PD-1/PD-L1) inhibitors. |
Drug: Pembrolizumab
Pembrolizumab intravenous (IV) infusion
Biological: GEN1046
GEN1046 IV infusion
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (ORR) [Up to 4 years]
ORR is defined as the percentage of participants with a confirmed response of partial response (PR) or complete response (CR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.
Secondary Outcome Measures
- Duration of Response (DOR) [Up to 4 years]
DOR is defined for responders as the time from initial onset of response to first progression event, defined as radiographic progression or death as per RECIST v1.1.
- Time to Response (TTR) [Up to 4 years]
TTR is defined as the time from first infusion of trial treatment to onset of response as per RECIST v1.1.
- Disease Control Rate (DCR) [Up to 4 years]
DCR is defined as the proportion of participants with a confirmed response of PR or CR or stable disease (SD) according to RECIST v1.1.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs) and as Per Severity [From first dose date up to 90 days after the study treatment]
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product as per CTCAE V5.0. TEAE is defined as an AE occurring or worsening between the first dose of study drug and 30 days after the last dose received.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have a histologically confirmed diagnosis of advanced (unresectable, recurrent, and/or metastatic) endometrial carcinoma that is incurable and for which prior standard first-line treatment has failed.
-
Prior to Cycle 1 Day 1 (C1D1), documentation of tumor dMMR/MSI-H status must be available based on local testing.
-
Must have progressed on or after at least 1 (but no more than 2) prior line(s) of a systemic chemotherapy regimen for unresectable and/or metastatic endometrial cancer of which at least 1 regimen of platinum-based treatment unless participant is ineligible for or intolerant to platinum.
-
Cohort A only: Must be treatment naive for CPIs including PD-1 or PD-L1 inhibitors and other immune CPIs (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT).
-
Cohort B only: Must have received and progressed on or after prior treatment with a PD-1/PD-L1 inhibitor alone or in combination. Moreover, the participant's duration of CPI containing treatment and best overall response (BOR) is known, and participant has received a minimum of 2 cycles of CPI.
Exclusion Criteria:
-
Histological diagnosis of carcinosarcoma, malignant mixed Műllerian tumor, endometrial leiomyosarcoma, or endometrial stromal sarcomas.
-
Any prior treatment with any type of antitumor vaccine, or autologous cell immunotherapy.
-
Radiotherapy within 14 days before the planned first dose of trial treatment with exception of palliative radiotherapy to bone lesions.
-
Treatment with an anticancer agent, including investigational vaccines within 28 days before or 5 times t1/2, whichever is shorter, prior to the planned first dose of trial treatment or is currently enrolled in an interventional trial.
-
Prior treatment with live, attenuated vaccines within 30 days prior to initiation of trial treatment.
-
Received granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support within 4 weeks before the planned first dose of trial treatment.
-
Cohort A only: Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40)
-
Cohort B only:
-
Known history of Grade 3 or higher immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy treatment
-
Exposure to any of the following prior therapies/treatments within the specified timeframes:
-
Prior exposure to immune CPIs other than anti-PD-1/anti-PD-L1 (eg, anti-CTLA-4, anti-LAG3, anti-TIGIT) or agents directed at costimulatory T-cell receptors (eg, 4-1BB, OX40)
-
PD-1/PD-L1 antibody within 28 days before the planned first dose of trial treatment
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Genmab
- BioNTech SE
Investigators
- Study Director: Study Official, Genmab
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GCT1046-05
- 2022-502453-33-00